Pre-Made Ipafricept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Wnt fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ipafricept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Wnt fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ipafricept (OMP-54F28) is a recombinant fusion protein (immunoadhesin) consisting of a combination of the extracellular ligand-binding domain of human FZD8 receptor and the human IgG1 Fc fragment (8, 11). Ipafricept inhibits Wnt signaling by acting as a decoy receptor while binding and sequestering Wnt ligands. Ipafricept binds to all Wnt proteins; therefore, it functions as a broad spectrum Wnt antagonist.
Wnt signaling pathway genes are crucial for cell fate determination and cell polarity during development. To date 19 Wnt ligands and 10 frizzled receptors have been characterized with many of these genes being implicated in tumor formation and progression. Ipafricept is a recombinant fusion protein with the extracellular part of human Frizzled 8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands. This truncated decoy receptor binds to a cystine-rich region of Wnt ligand and as a result it blocks the activation of the Wnt signaling. It can be used to treat a range of advanced solid tumors, including lung, colorectal and pancreatic tumors
| Products Name (INN Index) | Pre-Made Ipafricept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Wnt fused with human IGHG1 Fc (Fragment constant) |
|---|---|
| INN Name | ipafricept |
| Target | Wnt |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [FZD8 (frizzled class receptor 8, frizzled family receptor 8, Frizzled-8)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [FZD8 (frizzled class receptor 8, frizzled family receptor 8, Frizzled-8)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | OncoMed Pharmaceuticals (Redwood City CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Wnt |
| Package |
